Eledon submits tegoprubart islet transplantation IND; first patients enrolled
Eledon Pharmaceuticals submitted an IND to the FDA for an Eledon-sponsored registrational tegoprubart islet cell transplantation study for type 1 diabetes. It also enrolled first patients in a new investigator-initiated tegoprubart study in renal dysfunction patients.
Eledon submitted an IND to the FDA for its sponsored registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes. The company also said the first patients have been enrolled in a new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant. The first patient…